| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.2M | +17.7% | +20.4% |
| Cost of Revenue | $642K | +164.2% | +339.7% |
| R&D Expense | $23.6M | -11.7% | -42.5% |
| SG&A Expense | $10.9M | -30.0% | -37.1% |
| Operating Income | -$4.5M | +72.8% | +85.6% |
| Net Income | $63.9M | +313.0% | +195.1% |
| EPS (Basic) | $2.00 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.5M | -63.7% | -92.3% |
| Accounts Receivable | $538K | -24.1% | +159.9% |
| Current Assets | $133.9M | +904.1% | +167.1% |
| Total Assets | $233.9M | +26.3% | -1.9% |
| Current Liabilities | $287.1M | +22.4% | +6.1% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$60.6M | — | — |
| Capital Expenditures | $6K | — | — |
| Investing Cash Flow | $414K | — | — |
| Financing Cash Flow | $21.2M | — | — |
| Free Cash Flow | -$60.6M | — | — |
| +300.0% |
| +164.9% |
| EPS (Diluted) | $1.94 | +294.0% | +163.0% |
| $34.2M |
| +1.0% |
| — |
| Stockholders' Equity | -$274.1M | +22.7% | +6.2% |